

## Placebo and Nocebo Publications September 2020

1. Ambikaibalan, D., Quaade, A. S., Halling, A. S., Thyssen, J. P., & Egeberg, A. (2020). Placebo Response in Phase 3 Trials of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis. *Dermatology*, 1-8. doi:10.1159/000509295  
<https://www.ncbi.nlm.nih.gov/pubmed/32894834>
2. D'Amico, F., Solitano, V., Peyrin-Biroulet, L., & Danese, S. (2020). Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next? *Expert Opin Biol Ther*, 1-9. doi:10.1080/14712598.2020.1817374  
<https://www.ncbi.nlm.nih.gov/pubmed/32857634>
3. Evans, K., Romero, H., Spierings, E. L., & Katz, N. (2020). The relation between the placebo response, observed treatment effect, and failure to meet primary endpoint: A systematic review of clinical trials of preventative pharmacological migraine treatments. *Cephalalgia*, 333102420960020. doi:10.1177/0333102420960020  
<https://www.ncbi.nlm.nih.gov/pubmed/32960658>
4. Frangos, E., Ceko, M., Wang, B., Richards, E. A., Gracely, J. L., Colloca, L., Schweinhardt, P., & Bushnell, M. C. (2020). Neural effects of placebo analgesia in fibromyalgia patients and healthy individuals. *Pain*. doi:10.1097/j.pain.0000000000002064  
<https://www.ncbi.nlm.nih.gov/pubmed/32925593>
5. Frisaldi, E., Shaibani, A., & Benedetti, F. (2020). Understanding the mechanisms of placebo and nocebo effects. *Swiss Med Wkly*, 150, w20340. doi:10.4414/smw.2020.20340  
<https://www.ncbi.nlm.nih.gov/pubmed/32920787>
6. Hartmann, H., Rutgen, M., Riva, F., & Lamm, C. (2020). Another's pain in my brain: No evidence that placebo analgesia affects the sensory-discriminative component in empathy for pain. *Neuroimage*, 117397. doi:10.1016/j.neuroimage.2020.117397  
<https://www.ncbi.nlm.nih.gov/pubmed/32971262>
7. Hofler, C., Osmani, F., & Schienle, A. (2020). Placebo effects on the quantity and quality of relaxation training. *J Health Psychol*, 1359105320954238. doi:10.1177/1359105320954238  
<https://www.ncbi.nlm.nih.gov/pubmed/32873114>

8. Holper, L., & Hengartner, M. P. (2020). Comparative efficacy of placebos in short-term antidepressant trials for major depression: a secondary meta-analysis of placebo-controlled trials. *BMC Psychiatry*, 20(1), 437. doi:10.1186/s12888-020-02839-y  
<https://www.ncbi.nlm.nih.gov/pubmed/32894088>
9. Howick, J., Webster, R. K., Rees, J. L., Turner, R., Macdonald, H., Price, A., Evers, A. W. M., Bishop, F., Collins, G. S., Bokelmann, K., Hopewell, S., Knottnerus, A., Lamb, S., Madigan, C., Napadow, V., Papanikitas, A. N., & Hoffmann, T. (2020). TIDieR-Placebo: A guide and checklist for reporting placebo and sham controls. *PLoS Med*, 17(9), e1003294. doi:10.1371/journal.pmed.1003294  
<https://www.ncbi.nlm.nih.gov/pubmed/32956344>
10. Hull, M. (2020). Psychedelische Trips - auf Placebo! : Schlaganfallrisiko. *MMW Fortschr Med*, 162(16), 34. doi:10.1007/s15006-020-4377-9  
<https://www.ncbi.nlm.nih.gov/pubmed/32959291>
11. Loder, E. W., & McGeeney, B. (2020). Disentangling placebo effects in the treatment of migraine. *Nat Rev Neurol*. doi:10.1038/s41582-020-0406-7  
<https://www.ncbi.nlm.nih.gov/pubmed/32887960>
12. Luu, S., Province, H., Berry-Kravis, E., Hagerman, R., Hessel, D., Vaidya, D., Lozano, R., Rosselot, H., Erickson, C., Kaufmann, W. E., & Budimirovic, D. B. (2020). Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis. *Brain Sci*, 10(9). doi:10.3390/brainsci10090629  
<https://www.ncbi.nlm.nih.gov/pubmed/32932789>
13. Meissner, K., Lutter, D., von Toerne, C., Haile, A., Woods, S. C., Hoffmann, V., Ohmayer, U., Hauck, S. M., & Tschoep, M. H. (2020). Molecular classification of the placebo effect in nausea. *PLoS One*, 15(9), e0238533. doi:10.1371/journal.pone.0238533  
<https://www.ncbi.nlm.nih.gov/pubmed/32966280>
14. Momper, J. D., Green, D. J., Park, K., Burckart, G. J., & Snyder, D. L. (2020). Ethical Considerations for Pediatric Placebo-Controlled Trials: FDA Outcomes and Perspectives. *Ther Innov Regul Sci*. doi:10.1007/s43441-020-00214-3  
<https://www.ncbi.nlm.nih.gov/pubmed/32901443>
15. Nitzan, U., Carmeli, G., Chalamish, Y., Braw, Y., Kirsch, I., Shefet, D., Krieger, I., Mendlovic, S., Bloch, Y., & Lichtenberg, P. (2020). Open-Label placebo for the treatment of unipolar depression: Results from a randomized controlled trial. *J Affect Disord*, 276, 707-710. doi:10.1016/j.jad.2020.07.077  
<https://www.ncbi.nlm.nih.gov/pubmed/32871704>

16. Queiroz, N. S. F., Saad-Hossne, R., FrOes, R. S. B., Penna, F., Gabriel, S. B., Martins, A. L., & Teixeira, F. V. (2020). Discontinuation Rates Following a Switch from a Reference to a Biosimilar Biologic in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. *Arq Gastroenterol*. doi:10.1590/S0004-2803.202000000-45  
<https://www.ncbi.nlm.nih.gov/pubmed/32935741>
17. Solitano, V., D'Amico, F., Fiorino, G., Peyrin-Biroulet, L., & Danese, S. (2020). Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. *Expert Rev Clin Immunol*, 1-10. doi:10.1080/1744666X.2021.1826311  
<https://www.ncbi.nlm.nih.gov/pubmed/32954893>
18. Theodosis-Nobelos, P., Filotheidou, A., & Triantis, C. (2020). The placebo phenomenon and the underlying mechanisms. *Hormones (Athens)*. doi:10.1007/s42000-020-00243-5  
<https://www.ncbi.nlm.nih.gov/pubmed/32940864>
19. Thomaidou, M. A., Veldhuijzen, D. S., Meulders, A., & Evers, A. W. M. (2020). An experimental investigation into the mediating role of pain-related fear in boosting nocebo hyperalgesia. *Pain*. doi:10.1097/j.pain.0000000000002017  
<https://www.ncbi.nlm.nih.gov/pubmed/32910630>
20. Vollert, J., Cook, N. R., Kaptchuk, T. J., Sehra, S. T., Tobias, D. K., & Hall, K. T. (2020). Assessment of Placebo Response in Objective and Subjective Outcome Measures in Rheumatoid Arthritis Clinical Trials. *JAMA Netw Open*, 3(9), e2013196. doi:10.1001/jamanetworkopen.2020.13196  
<https://www.ncbi.nlm.nih.gov/pubmed/32936297>